Found 3 clinical trials
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease
, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of
- 114 views
- 29 Apr, 2022
- 12 locations
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy
In Fabry disease (FD), -galactosidase A deficiency leads to the accumulation of globotriaosylceramide (Lyso-Gb3 and Gb3), triggering a pathologic cascade that causes progressive damage to
- 0 views
- 05 Feb, 2021
- 1 location
Early Detection and Follow-Up of Patients With Fabry's Disease
deepen our knowledge of the correlation among Lyso-Gb3, genotype and phenotype. Better understanding of the pathophysiology of FD. To sum up, the results of the study will make a significant
- 0 views
- 28 Apr, 2021
- 1 location